The convergence of therapeutic drug monitoring and pharmacogenetic testing to optimize efavirenz therapy

Therapeutic Drug Monitoring

Volumn 32, Issue 5, 2010, Pages 579-585

  Figueroa, Salvador Cabrera ^a,b   De Gatta, María Fernández ^c   García, Lorena Hernández ^d   Hurlé, Alfonso Domínguez Gil ^a,c   Bernal, Carmen Bustos ^a   Correa, Rosa Sepúlveda ^c   Sánchez, María José García ^c  

^a HOSPITAL UNIVERSITARIO DE SALAMANCA   (Spain)

^b UNIVERSIDAD AUSTRAL DE CHILE   (Chile)

^c UNIVERSITY OF SALAMANCA   (Spain)

^d Progenika Biopharma SA   (Spain)

Author keywords

CNS side effects; efavirenz; genetic polymorphism; pharmacogenetics; therapeutic drug monitoring

Indexed keywords

CYTOCHROME P450 2B6; EFAVIRENZ;

ADULT; ARTICLE; CENTRAL NERVOUS SYSTEM DISEASE; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG MONITORING; GENETIC POLYMORPHISM; GENOTYPE; HOMOZYGOSITY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MAJOR CLINICAL STUDY; PHARMACOGENETICS; PHENOTYPE; PRIORITY JOURNAL;

ADULT; ANTI-HIV AGENTS; ARYL HYDROCARBON HYDROXYLASES; BENZOXAZINES; DRUG MONITORING; FEMALE; GENOTYPE; HIV INFECTIONS; HUMANS; MALE; MIDDLE AGED; OXIDOREDUCTASES, N-DEMETHYLATING; POLYMORPHISM, GENETIC;

EID: 77957282498     PISSN: 01634356     EISSN: 15363694     Source Type: Journal    
DOI: 10.1097/FTD.0b013e3181f0634c     Document Type: Article

References (39)

1. Weintrob AC, Grandits GA, Agan BK, et al. Virologic response differences between African Americans and European Americans initiating highly active antiretroviral therapy with equal access to care. J Acquir Immune Defic Syndr. 2009;52:574-580.
2. Slish JC, Catanzaro LM, Ma Q, et al. Update on the pharmacokinetic aspects of antiretroviral agents: implications in therapeutic drug monitoring. Curr Pharm Des. 2006;12:1129-1145.
3. Marzolini C, Telenti A, Decosterd LA, et al. Efavirenz plasma levels can predict treatment failure and central nervous system side effects in HIV- 1-infected patients. AIDS. 2001;15:71-75. (Pubitemid 32055781)
4. Ingelman-Sundberg M, Oscarson M, McLellan RA. Polymorphic human cytochrome P450 enzymes; an opportunity for individualized drug treatment. Trends Pharmacol Sci. 1999;20:342-349.
5. Evans WE, Relling MV. Pharmacogenomics: translating functional genomics into rational therapeutics. Science. 1999;286:487-491.
6. Ward BA, Gorski JC, Jones DR, et al. The cytochrome P450 2B6 (CYP2B6) is the main catalyst of efavirenz primary and secondary metabolism: implication for HIV/AIDS therapy and utility of efavirenz as a substrate marker of CYP2B6 catalytic activity. J Pharmacol Exp Ther. 2003;306:287-300.
7. Wang J, Sönnerborg A, Rane A, et al. Identification of a novel specific CYP2B6 allele in Africans causing impaired metabolism of the HIV drug efavirenz. Pharmacogenet Genomics. 2006;16:191-198.
8. Rohrbacher M, Kirchhof A, Geisslinger G, et al. Pyrosequencing-based screening for genetic polymorphisms in cytochrome P450 2B6 of potential clinical relevance. Pharmacogenomics. 2006;7:995-1002.
9. Lamba V, Lamba J, Yasuda K, et al. Hepatic CYP2B6 expression: gender and ethnic differences and relationship to CYP2B6 genotype and CAR (constitutive androstane receptor) expression. J Pharmacol Exp Ther. 2003;307:906-922.
10. Lang T, Klein K, Richter T, et al. Multiple novel non-synonymous CYP2B6 gene polymorphisms in Caucasians: demonstration of phenotypic null alleles. J Pharmacol Exp Ther. 2004;311:34-43.
11. Zukunft J, Lang T, Richter T, et al. A natural CYP2B6 TATA box polymorphism (-82T- C) leading to enhanced transcription and relocation of the transcriptional start site. Mol Pharmacol. 2005;67: 1772-1782.
12. Haas DW, Ribaudo HJ, Kim RB, et al. Pharmacogenetics of efavirenz and central nervous system side effects: an Adult AIDS Clinical Trials Group study. AIDS. 2004;18:2391-2400.
13. Nyakutira C, Röshammar D, Chigutsa E, et al. High prevalence of the CYP2B6 516G-.T(6) variant and effect on the population pharmacokinetics of efavirenz in HIV/AIDS outpatients in Zimbabwe. Eur J Clin Pharmacol. 2008;64:357-365.
14. Rotger M, Tegude H, Colombo S, et al. Predictive value of known and novel alleles of CYP2B6 for efavirenz plasma concentrations in HIVinfected individuals. Clin Pharmacol Ther. 2007;81:557-566.
15. Rodriguez-Novoa S, Barreiro P, Rendón A, et al. Influence of 516G.T polymorphisms at the gene encoding the CYP450-2B6 isoenzyme on efavirenz plasma concentrations in HIV-infected subjects. Clin Infect Dis. 2005;40:1358-1361.
16. Rotger M, Telenti A. Optimizing efavirenz treatment: CYP2B6 genotyping or therapeutic drug monitoring? Eur J Clin Pharmacol. 2008;64:335-336.
17. Saitoh A, Singh KK, Powell CA, et al. An MDR1-3435 variant is associated with higher plasma nelfinavir levels and more rapid virologic response in HIV-1 infected children. AIDS. 2005;19:371-380.
18. Motsinger AA, Ritchie MD, Shafer RW, et al. Multilocus genetic interactions and response to efavirenz-containing regimens: an adult AIDS clinical trials group study. Pharmacogenet Genomics. 2006;16: 837-845.
19. Fellay J, Marzolini C, Meaden ER, et al. Response to antiretroviral treatment in HIV-1-infected individuals with allelic variants of the multidrug resistance transporter 1: a pharmacogenetics study. Lancet. 2002;359:30-36.
20. Winzer R, Langmann P, Zilly M, et al. No influence of the P-glycoprotein genotype (MDR1 C3435T) on plasma levels of lopinavir and efavirenz during antiretroviral treatment. Eur J Med Res. 2003;8:531-534.
21. Ensom MH, Chang TK, Patel P. Pharmacogenetics: the therapeutic drug monitoring of the future? Clin Pharmacokinet. 2001;40:783-802.
22. Sjö qvist F, Eliasson E. The convergence of conventional therapeutic drug monitoring and pharmacogenetic testing in personalized medicine: focus on antidepressants. Clin Pharmacol Ther. 2007;81:899-902.
23. Institut d́Investigacions Biomèdiques August Pi i Sunyer, Institut Cĺ?nic de Medicina i Dermatoloǵ?a. Interacciones HIV.com. Available at: www.interaccioneshiv.com. Accessed January 25, 2010.
24. Knobel H, Alonso J, Casado JL, et al. Validation of a simplified medication adherence questionnaire in a large cohort of HIV-infected patients: the GEEMA Study. AIDS. 2002;16:605-613.
25. Csajka C, Marzolini C, Fattinger K, et al. Population pharmacokinetics and effects of efavirenz in patients with human immunodeficiency virus infection. Clin Pharmacol Ther. 2003;73:20-30.
26. Colombo S, Guignard N, Marzolini C, et al. Determination of the new HIV-protease inhibitor atazanavir by liquid chromatography after solidphase extraction. J Chromatogr B Analyt Technol Biomed Life Sci. 2004; 810:25-34.
27. Pfister M, Labbé L, Hammer SM, et al. Population pharmacokinetics and pharmacodynamics of efavirenz, nelfinavir, and indinavir: Adult AIDS Clinical Trial Group Study 398. Antimicrob Agents Chemother. 2003;47: 130-137.
28. Progenika: genetic testing for personalized medicine. Available at: www.progenika.com. Accessed May 11, 2010.
29. Tejedor D, Castillo S, Mozas P, et al. Reliable low-density DNA array based on allele-specific probes for detection of 118 mutations causing familial hypercholesterolemia. Clin Chem. 2005;51:1137-1144.
30. Cabrera SE, Cordero M, Iglesias A, et al. Efavirenz-rifampicin interaction: therapeutic drug monitoring to efavirenz dosage optimization in HIV/TBC patients. AIDS. 2008;22:2549-2551.
31. Rakhmanina NY, van den Anker JN. Efavirenz in the therapy of HIV infection. Expert Opin Drug Metab Toxicol. 2010;6:95-103.
32. Home page of the Human Cytochrome P450 (CYP) Allele Nomenclature Committee. Available at: www.cypalleles.ki.se/cyp2b6.htm. Accessed February 25, 2010.
33. Gatanaga H, Hayashida T, Tsuchiya K, et al. Successful efavirenz dose reduction in HIV type 1-infected individuals with cytochrome P450 2B66 and26. Clin Infect Dis. 2007;45:1230-1237.
34. Tsuchiya K, Gatanaga H, Tachikawa N, et al. Homozygous CYP2B66 (Q172H and K262R) correlates with high plasma efavirenz concentrations in HIV-1 patients treated with standard efavirenz-containing regimens. Biochem Biophys Res Commun. 2004;319:1322-1326.
35. Rotger M, Colombo S, Furrer H, et al. Influence of CYP2B6 polymorphism on plasma and intracellular concentrations and toxicity of efavirenz and nevirapine in HIV-infected patients. Pharmacogenet Genomics. 2005;15:1-5.
36. Rodŕ?guez-Novoa S, Barreiro P, Jiménez-Nácher I, et al. Overview of the pharmacogenetics of HIV therapy. Pharmacogenomics J. 2006;6:234-245.
37. Department of Health and Human Services. Panel on Antiretroviral Guidelines for Adult and Adolescents. Guidelines for the use of antiretroviral agents in HIV-infected adults and adolescents. December 1, 2009. Available at: www.aidsinfo.nih.gov. Accessed February 25, 2010.
38. Cabrera SE, Santos D, Valverde MP, et al. Influence of the cytochrome P450 2B6 genotype on population pharmacokinetics of efavirenz in human immunodeficiency virus patients. Antimicrob Agents Chemother. 2009;53:2791-2798.
39. Torno MS, Witt MD, Saitoh A, et al. Successful use of reduced-dose efavirenz in a patient with human immunodeficiency virus infection: case report and review of the literature. Pharmacotherapy. 2008;28:782-787.